家族性大腸腺腫症治療の世界市場レポート 2025年

家族性大腸腺腫症（FAP）治療市場規模は今後数年で急成長が見込まれます。2029年にはCAGR11.4%で23億1,000万米ドルに成長します。予測期間に予測される成長は、遺伝子治療の利用拡大、効果的な治療オプションに対する需要の高まり、遺伝性疾患に対する意識の高まり、ヘルスケアインフラの拡大、遺伝子検査とカウンセリングの需要増加などの要因によるものです。この期間の主な動向には、治療法の進歩、遺伝子研究の発展、革新的技術の使用、集学的治療モデルの統合、個別化医療アプローチの人気の高まりなどがあります。

ヘルスケア支出の増加は、家族性大腸腺腫症（FAP）治療市場の拡大を促進すると予想されます。ヘルスケア支出とは、医療サービス、治療、医薬品、医療関連インフラに関連する総費用を指し、個人、政府、民間団体が健康状態を維持・改善するために負担するものです。ヘルスケア支出の増加は、人口の高齢化と医療技術の進歩によるところが大きいです。平均寿命が延びるにつれて、長期ケア、慢性疾患管理、頻繁な医療介入の必要性が高まり、ヘルスケア費用の増加につながります。ヘルスケア支出の急増はFAP治療の研究開発を促進し、早期発見、疾病管理、患者の転帰を向上させる遺伝子検査、標的治療、低侵襲手術などの技術革新をもたらします。例えば、2024年12月、米国の連邦機関であるメディケア＆メディケイドサービスセンターは、米国のメディケア支出が8.1％増加し、1兆298億米ドルに達し、国民医療費（NHE）全体の21％を占めたと報告しました。このように、ヘルスケア支出の増加がFAP治療市場の成長を牽引しています。

低侵襲手術の増加は、家族性腺腫症（FAP）治療市場の成長を加速させると予想されています。低侵襲手術は、従来の手術と比較して、より小さな切開、特殊な器具、または画像ガイダンスを使用して、より少ない外傷、より迅速な回復時間、およびより少ないリスクで状態を診断または治療する医療技術を含みます。低侵襲手術の採用が増加している背景には、医療技術の進歩や、より早い回復を求める患者の需要の増加があります。手術手技、ロボット工学、画像技術の革新により、より小さな切開による手術が可能になり、合併症の減少や入院期間の短縮が図られています。これらの治療法は、早期発見、正確な切除、合併症の減少を可能にすることで、FAP治療におけるポリープ切除とサーベイランスを強化し、病気の進行を遅らせ、大規模な手術の必要性を減らすのに役立っています。例えば、2023年、米国形成外科学会は、米国における低侵襲手術の前年比7％増を報告しています。その結果、低侵襲手術の増加がFAP治療市場の成長に寄与しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界家族性大腸腺腫症治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の家族性大腸腺腫症治療市場：成長率分析
• 世界の家族性大腸腺腫症治療市場の実績：規模と成長, 2019-2024
• 世界の家族性大腸腺腫症治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界家族性大腸腺腫症治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の家族性大腸腺腫症治療市場：製品タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• イコサペント
• エフロルニチン塩酸塩
• アスピリン
• セツキシマブ経口製剤（CEQ）-508
• その他の製品タイプ
• 世界の家族性大腸腺腫症治療市場疾患サブタイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 軽症FAP
• 家族性大腸腺腫症
• ガードナー症候群
• ターコット症候群
• 世界の家族性大腸腺腫症治療市場症状別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 血便
• 原因不明の下痢
• 腹部のけいれん
• 膨満感
• 減量
• 無気力と嘔吐
• 世界の家族性大腸腺腫症治療市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 大腸がん予防
• 遺伝カウンセリング
• 外科的治療
• 世界の家族性大腸腺腫症治療市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• クリニック
• 病院
• 診断センター
• 在宅ヘルスケア
• その他のエンドユーザー
• 世界の家族性大腸腺腫症治療市場イコサペントのサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• 高純度イコサペント
• 複合製剤
• 徐放性イコサペント
• 世界の家族性大腸腺腫症治療市場エフロルニチン塩酸塩の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口エフロルニチン塩酸塩
• 局所用エフロルニチン塩酸塩
• 静脈内エフロルニチン塩酸塩
• 世界の家族性大腸腺腫症治療市場アスピリンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 低用量アスピリン療法
• 腸溶性アスピリン
• 緩衝アスピリン
• 世界の家族性大腸腺腫症治療市場CEQ-508のサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• 単剤療法CEQ-508
• 補助的CEQ-508療法
• 標的CEQ-508製剤
• 世界の家族性大腸腺腫症治療市場、その他の製品タイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 遺伝子検査キットとバイオマーカー
• 内視鏡監視装置
• 外科器具と医療インプラント
• プロバイオティクスとマイクロバイオームモジュレーター
• 排便準備ソリューション
• 栄養補助食品と栄養補助食品
• 高周波アブレーション（RFA）装置
• 凍結療法およびレーザー治療システム
• 人工知能（AI）支援診断ツール
• 患者モニタリングとデジタルヘルスソリューション

第7章 地域別・国別分析

• 世界の家族性大腸腺腫症治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の家族性大腸腺腫症治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 家族性大腸腺腫症治療市場：競合情勢
• 家族性大腸腺腫症治療市場：企業プロファイル
  • Mayo Clinic Overview, Products and Services, Strategy and Financial Analysis
  • Mount Sinai Health System Overview, Products and Services, Strategy and Financial Analysis
  • Johns Hopkins Medicine Overview, Products and Services, Strategy and Financial Analysis
  • Cleveland Clinic Overview, Products and Services, Strategy and Financial Analysis
  • UCLA Health Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Houston Methodist Hospital
• Scripps Health
• Duke University Health System
• Texas Children's Hospital
• Massachusetts General Hospital
• Inova Health Care Services
• Brigham and Women's Hospital
• Stanford Health Care
• Barnes-Jewish Hospital
• Northwestern Medicine
• Geisinger Health
• Max Healthcare
• Sapience Therapeutics Inc.
• Frederick Gastroenterology Associates PA
• Therapyx

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 家族性大腸腺腫症治療市場2029：新たな機会を提供する国
• 家族性大腸腺腫症治療市場2029：新たな機会を提供するセグメント
• 家族性大腸腺腫症治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Familial adenomatous polyposis (FAP) treatment involves both medical and surgical methods to manage this genetic condition, which is characterized by the development of numerous precancerous polyps in the colon and rectum. The primary goal of treatment is to prevent the onset of colorectal cancer, which almost certainly develops if left untreated.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main treatment products for familial adenomatous polyposis include icosapent, eflornithine hydrochloride, aspirin, cetuximab oral formulation (ceq)-508, and others. Icosapent is a purified derivative of eicosapentaenoic acid (EPA), primarily used to lower triglyceride levels. It is used in the treatment of attenuated FAP, familial adenomatous polyposis, Gardner syndrome, and Turcot syndrome. Icosapent is effective in managing symptoms such as bloody stool, unexplained diarrhea, abdominal cramps, bloating, weight loss, lethargy, and vomiting. It is also used for colorectal cancer prevention, genetic counseling, and surgical interventions by various end-users, including clinics, hospitals, diagnostic centers, home healthcare services, and others.

The familial adenomatous polyposis treatment market research report is one of a series of new reports from The Business Research Company that provides familial adenomatous polyposis treatment market statistics, including familial adenomatous polyposis treatment industry global market size, regional shares, competitors with a familial adenomatous polyposis treatment market share, detailed familial adenomatous polyposis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the familial adenomatous polyposis treatment industry. This familial adenomatous polyposis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The familial adenomatous polyposis (FAP) treatment market size has grown rapidly in recent years. It will grow from $1.34 billion in 2024 to $1.50 billion in 2025 at a compound annual growth rate (CAGR) of 11.5%. The growth observed in the historic period can be attributed to several factors, including the increasing prevalence of familial adenomatous polyposis, excessive tobacco consumption, a rising incidence of genetic disorders, greater healthcare awareness and legislative changes, and the growing prevalence of sedentary lifestyles.

The familial adenomatous polyposis (FAP) treatment market size is expected to see rapid growth in the next few years. It will grow to $2.31 billion in 2029 at a compound annual growth rate (CAGR) of 11.4%. The growth projected for the forecast period can be attributed to factors such as the expanding use of gene therapy, rising demand for effective treatment options, growing awareness of genetic diseases, the expansion of healthcare infrastructure, and increasing demand for genetic testing and counseling. Key trends during this period include advancements in treatment methods, developments in genetic research, the use of innovative techniques, the integration of multidisciplinary care models, and the rising popularity of personalized medicine approaches.

The growing healthcare expenditure is expected to drive the expansion of the familial adenomatous polyposis (FAP) treatment market. Healthcare spending refers to the total costs associated with medical services, treatments, pharmaceuticals, and health-related infrastructure, which are incurred by individuals, governments, and private entities to maintain and improve health outcomes. This rise in healthcare spending is largely due to an aging population and ongoing advancements in medical technology. As life expectancy increases, there is a greater need for long-term care, chronic disease management, and frequent medical interventions, leading to higher healthcare costs. The surge in healthcare spending fosters research and development in FAP treatment, resulting in innovations such as genetic testing, targeted therapies, and minimally invasive procedures that enhance early detection, disease management, and patient outcomes. For example, in December 2024, the Centers for Medicare & Medicaid Services, a US-based federal agency, reported that Medicare spending in the US rose by 8.1%, reaching $1,029.8 billion, which accounted for 21% of total national health expenditures (NHE). Thus, the increase in healthcare spending is driving the growth of the FAP treatment market.

The rise in minimally invasive procedures is expected to accelerate the growth of the familial adenomatous polyposis (FAP) treatment market. Minimally invasive procedures involve medical techniques that use smaller incisions, specialized instruments, or imaging guidance to diagnose or treat conditions with less trauma, quicker recovery times, and reduced risks compared to traditional surgery. The growing adoption of minimally invasive procedures is driven by advances in medical technology and increasing patient demand for faster recovery. Innovations in surgical techniques, robotics, and imaging technologies have enabled procedures with smaller incisions, reducing complications and shortening hospital stays. These procedures enhance polyp removal and surveillance in FAP treatment by enabling early detection, precise excision, and fewer complications, which help delay disease progression and reduce the need for extensive surgeries. For instance, in 2023, the American Society of Plastic Surgeons reported a 7% year-over-year growth in minimally invasive procedures in the USA. Consequently, the rise of minimally invasive procedures is contributing to the growth of the FAP treatment market.

Major companies in the familial adenomatous polyposis (FAP) treatment market are making significant strides in therapeutic approaches to enhance patient outcomes and introduce innovative solutions. These advancements include new drug formulations and targeted therapies aimed at reducing polyp formation and slowing disease progression. For example, in June 2024, Biodexa Pharmaceuticals PLC, a UK-based biopharmaceutical company, shared promising results from its Phase 2 clinical trial of eRapa for FAP treatment. The trial demonstrated a 75% non-progression rate and a 17% median reduction in polyp burden over 12 months. In Cohort 2, participants experienced an even higher 81% non-progression rate and a 29% reduction in polyps with a specific dosing regimen. The treatment was well-tolerated, with a 95% compliance rate. These promising results pave the way for a Phase 3 trial involving approximately 168 high-risk FAP patients, potentially shifting treatment strategies from surgery to effective medical therapy.

Major players in the familial adenomatous polyposis treatment market are Mayo Clinic, Mount Sinai Health System, Johns Hopkins Medicine, Cleveland Clinic, UCLA Health, Houston Methodist Hospital, Scripps Health, Duke University Health System, Texas Children's Hospital, Massachusetts General Hospital, Inova Health Care Services, Brigham and Women's Hospital, Stanford Health Care, Barnes-Jewish Hospital, Northwestern Medicine, Geisinger Health, Max Healthcare, Sapience Therapeutics Inc., Frederick Gastroenterology Associates PA, Therapyx.

North America was the largest region in the familial adenomatous polyposis (FAP) treatment market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in familial adenomatous polyposis treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the familial adenomatous polyposis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The familial adenomatous polyposis treatment market consists of sales of non-steroidal anti-inflammatory drugs, chemo preventive agents and targeted therapies. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Familial Adenomatous Polyposis Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on familial adenomatous polyposis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for familial adenomatous polyposis treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The familial adenomatous polyposis treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product Type: Icosapent; Eflornithine Hydrochloride; Aspirin; Cetuximab Oral Formulation (CEQ)-508; Other Product Types
• 2) By Disease Subtype: Attenuated FAP; Familial Adenomatous Polyposis; Gardner Syndrome; Turcot Syndrome
• 3) By Symptoms: Bloody Stool; Unexplained Diarrhea; Abdominal Cramps; Bloating ; Weight Loss; Lethargy And Vomiting
• 4) By Application: Colorectal Cancer Prevention; Genetic Counseling; Surgical Treatment
• 5) By End-Users: Clinics; Hospitals; Diagnostic Centres; Home Healthcare; Other End-Users
• Subsegments:
• 1) By Icosapent: High-Purity Icosapent; Combination Formulations; Extended-Release Icosapent
• 2) By Eflornithine Hydrochloride: Oral Eflornithine Hydrochloride; Topical Eflornithine Hydrochloride; Intravenous Eflornithine Hydrochloride
• 3) By Aspirin: Low-Dose Aspirin Therapy; Enteric-Coated Aspirin; Buffered Aspirin
• 4) By CEQ-508: Monotherapy CEQ-508; Adjunctive CEQ-508 Therapy; Targeted CEQ-508 Formulations
• 5) By Other Product Types: Genetic Testing Kits And Biomarkers; Endoscopic Surveillance Devices; Surgical Instruments And Medical Implants; Probiotics And Microbiome Modulators; Bowel Preparation Solutions; Dietary Supplements And Nutraceuticals; Radiofrequency Ablation (RFA) Devices; Cryotherapy And Laser Therapy Systems; Artificial Intelligence (AI)-Assisted Diagnostic Tools; Patient Monitoring And Digital Health Solutions
• Companies Mentioned: Mayo Clinic; Mount Sinai Health System; Johns Hopkins Medicine; Cleveland Clinic; UCLA Health
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Familial Adenomatous Polyposis Treatment Market Characteristics

3. Familial Adenomatous Polyposis Treatment Market Trends And Strategies

4. Familial Adenomatous Polyposis Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Familial Adenomatous Polyposis Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Familial Adenomatous Polyposis Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Familial Adenomatous Polyposis Treatment Market Growth Rate Analysis
• 5.4. Global Familial Adenomatous Polyposis Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Familial Adenomatous Polyposis Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Familial Adenomatous Polyposis Treatment Total Addressable Market (TAM)

6. Familial Adenomatous Polyposis Treatment Market Segmentation

• 6.1. Global Familial Adenomatous Polyposis Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Icosapent
• Eflornithine Hydrochloride
• Aspirin
• Cetuximab Oral Formulation (CEQ)-508
• Other Product Types
• 6.2. Global Familial Adenomatous Polyposis Treatment Market, Segmentation By Disease Subtype, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Attenuated FAP
• Familial Adenomatous Polyposis
• Gardner Syndrome
• Turcot Syndrome
• 6.3. Global Familial Adenomatous Polyposis Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bloody Stool
• Unexplained Diarrhea
• Abdominal Cramps
• Bloating
• Weight Loss
• Lethargy And Vomiting
• 6.4. Global Familial Adenomatous Polyposis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Colorectal Cancer Prevention
• Genetic Counseling
• Surgical Treatment
• 6.5. Global Familial Adenomatous Polyposis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Clinics
• Hospitals
• Diagnostic Centres
• Home Healthcare
• Other End-Users
• 6.6. Global Familial Adenomatous Polyposis Treatment Market, Sub-Segmentation Of Icosapent, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• High-Purity Icosapent
• Combination Formulations
• Extended-Release Icosapent
• 6.7. Global Familial Adenomatous Polyposis Treatment Market, Sub-Segmentation Of Eflornithine Hydrochloride, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Eflornithine Hydrochloride
• Topical Eflornithine Hydrochloride
• Intravenous Eflornithine Hydrochloride
• 6.8. Global Familial Adenomatous Polyposis Treatment Market, Sub-Segmentation Of Aspirin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Low-Dose Aspirin Therapy
• Enteric-Coated Aspirin
• Buffered Aspirin
• 6.9. Global Familial Adenomatous Polyposis Treatment Market, Sub-Segmentation Of CEQ-508, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monotherapy CEQ-508
• Adjunctive CEQ-508 Therapy
• Targeted CEQ-508 Formulations
• 6.10. Global Familial Adenomatous Polyposis Treatment Market, Sub-Segmentation Of Other Product Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Genetic Testing Kits And Biomarkers
• Endoscopic Surveillance Devices
• Surgical Instruments And Medical Implants
• Probiotics And Microbiome Modulators
• Bowel Preparation Solutions
• Dietary Supplements And Nutraceuticals
• Radiofrequency Ablation (RFA) Devices
• Cryotherapy And Laser Therapy Systems
• Artificial Intelligence (AI)-Assisted Diagnostic Tools
• Patient Monitoring And Digital Health Solutions

7. Familial Adenomatous Polyposis Treatment Market Regional And Country Analysis

• 7.1. Global Familial Adenomatous Polyposis Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Familial Adenomatous Polyposis Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Familial Adenomatous Polyposis Treatment Market

• 8.1. Asia-Pacific Familial Adenomatous Polyposis Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Familial Adenomatous Polyposis Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Familial Adenomatous Polyposis Treatment Market, Segmentation By Disease Subtype, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Familial Adenomatous Polyposis Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Familial Adenomatous Polyposis Treatment Market

• 9.1. China Familial Adenomatous Polyposis Treatment Market Overview
• 9.2. China Familial Adenomatous Polyposis Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Familial Adenomatous Polyposis Treatment Market, Segmentation By Disease Subtype, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Familial Adenomatous Polyposis Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Familial Adenomatous Polyposis Treatment Market

• 10.1. India Familial Adenomatous Polyposis Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Familial Adenomatous Polyposis Treatment Market, Segmentation By Disease Subtype, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Familial Adenomatous Polyposis Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Familial Adenomatous Polyposis Treatment Market

• 11.1. Japan Familial Adenomatous Polyposis Treatment Market Overview
• 11.2. Japan Familial Adenomatous Polyposis Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Familial Adenomatous Polyposis Treatment Market, Segmentation By Disease Subtype, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Familial Adenomatous Polyposis Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Familial Adenomatous Polyposis Treatment Market

• 12.1. Australia Familial Adenomatous Polyposis Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Familial Adenomatous Polyposis Treatment Market, Segmentation By Disease Subtype, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Familial Adenomatous Polyposis Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Familial Adenomatous Polyposis Treatment Market

• 13.1. Indonesia Familial Adenomatous Polyposis Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Familial Adenomatous Polyposis Treatment Market, Segmentation By Disease Subtype, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Familial Adenomatous Polyposis Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Familial Adenomatous Polyposis Treatment Market

• 14.1. South Korea Familial Adenomatous Polyposis Treatment Market Overview
• 14.2. South Korea Familial Adenomatous Polyposis Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Familial Adenomatous Polyposis Treatment Market, Segmentation By Disease Subtype, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Familial Adenomatous Polyposis Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Familial Adenomatous Polyposis Treatment Market

• 15.1. Western Europe Familial Adenomatous Polyposis Treatment Market Overview
• 15.2. Western Europe Familial Adenomatous Polyposis Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Familial Adenomatous Polyposis Treatment Market, Segmentation By Disease Subtype, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Familial Adenomatous Polyposis Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Familial Adenomatous Polyposis Treatment Market

• 16.1. UK Familial Adenomatous Polyposis Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Familial Adenomatous Polyposis Treatment Market, Segmentation By Disease Subtype, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Familial Adenomatous Polyposis Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Familial Adenomatous Polyposis Treatment Market

• 17.1. Germany Familial Adenomatous Polyposis Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Familial Adenomatous Polyposis Treatment Market, Segmentation By Disease Subtype, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Familial Adenomatous Polyposis Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Familial Adenomatous Polyposis Treatment Market

• 18.1. France Familial Adenomatous Polyposis Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Familial Adenomatous Polyposis Treatment Market, Segmentation By Disease Subtype, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Familial Adenomatous Polyposis Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Familial Adenomatous Polyposis Treatment Market

• 19.1. Italy Familial Adenomatous Polyposis Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Familial Adenomatous Polyposis Treatment Market, Segmentation By Disease Subtype, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Familial Adenomatous Polyposis Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Familial Adenomatous Polyposis Treatment Market

• 20.1. Spain Familial Adenomatous Polyposis Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Familial Adenomatous Polyposis Treatment Market, Segmentation By Disease Subtype, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Familial Adenomatous Polyposis Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Familial Adenomatous Polyposis Treatment Market

• 21.1. Eastern Europe Familial Adenomatous Polyposis Treatment Market Overview
• 21.2. Eastern Europe Familial Adenomatous Polyposis Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Familial Adenomatous Polyposis Treatment Market, Segmentation By Disease Subtype, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Familial Adenomatous Polyposis Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Familial Adenomatous Polyposis Treatment Market

• 22.1. Russia Familial Adenomatous Polyposis Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Familial Adenomatous Polyposis Treatment Market, Segmentation By Disease Subtype, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Familial Adenomatous Polyposis Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Familial Adenomatous Polyposis Treatment Market

• 23.1. North America Familial Adenomatous Polyposis Treatment Market Overview
• 23.2. North America Familial Adenomatous Polyposis Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Familial Adenomatous Polyposis Treatment Market, Segmentation By Disease Subtype, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Familial Adenomatous Polyposis Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Familial Adenomatous Polyposis Treatment Market

• 24.1. USA Familial Adenomatous Polyposis Treatment Market Overview
• 24.2. USA Familial Adenomatous Polyposis Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Familial Adenomatous Polyposis Treatment Market, Segmentation By Disease Subtype, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Familial Adenomatous Polyposis Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Familial Adenomatous Polyposis Treatment Market

• 25.1. Canada Familial Adenomatous Polyposis Treatment Market Overview
• 25.2. Canada Familial Adenomatous Polyposis Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Familial Adenomatous Polyposis Treatment Market, Segmentation By Disease Subtype, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Familial Adenomatous Polyposis Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Familial Adenomatous Polyposis Treatment Market

• 26.1. South America Familial Adenomatous Polyposis Treatment Market Overview
• 26.2. South America Familial Adenomatous Polyposis Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Familial Adenomatous Polyposis Treatment Market, Segmentation By Disease Subtype, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Familial Adenomatous Polyposis Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Familial Adenomatous Polyposis Treatment Market

• 27.1. Brazil Familial Adenomatous Polyposis Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Familial Adenomatous Polyposis Treatment Market, Segmentation By Disease Subtype, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Familial Adenomatous Polyposis Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Familial Adenomatous Polyposis Treatment Market

• 28.1. Middle East Familial Adenomatous Polyposis Treatment Market Overview
• 28.2. Middle East Familial Adenomatous Polyposis Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Familial Adenomatous Polyposis Treatment Market, Segmentation By Disease Subtype, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Familial Adenomatous Polyposis Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Familial Adenomatous Polyposis Treatment Market

• 29.1. Africa Familial Adenomatous Polyposis Treatment Market Overview
• 29.2. Africa Familial Adenomatous Polyposis Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Familial Adenomatous Polyposis Treatment Market, Segmentation By Disease Subtype, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Familial Adenomatous Polyposis Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Familial Adenomatous Polyposis Treatment Market Competitive Landscape And Company Profiles

• 30.1. Familial Adenomatous Polyposis Treatment Market Competitive Landscape
• 30.2. Familial Adenomatous Polyposis Treatment Market Company Profiles
  • 30.2.1. Mayo Clinic Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Mount Sinai Health System Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Johns Hopkins Medicine Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Cleveland Clinic Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. UCLA Health Overview, Products and Services, Strategy and Financial Analysis

31. Familial Adenomatous Polyposis Treatment Market Other Major And Innovative Companies

• 31.1. Houston Methodist Hospital
• 31.2. Scripps Health
• 31.3. Duke University Health System
• 31.4. Texas Children's Hospital
• 31.5. Massachusetts General Hospital
• 31.6. Inova Health Care Services
• 31.7. Brigham and Women's Hospital
• 31.8. Stanford Health Care
• 31.9. Barnes-Jewish Hospital
• 31.10. Northwestern Medicine
• 31.11. Geisinger Health
• 31.12. Max Healthcare
• 31.13. Sapience Therapeutics Inc.
• 31.14. Frederick Gastroenterology Associates PA
• 31.15. Therapyx

32. Global Familial Adenomatous Polyposis Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Familial Adenomatous Polyposis Treatment Market

34. Recent Developments In The Familial Adenomatous Polyposis Treatment Market

35. Familial Adenomatous Polyposis Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Familial Adenomatous Polyposis Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Familial Adenomatous Polyposis Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Familial Adenomatous Polyposis Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer
• 250617_r34848_Familial_Adenomatous_Polyposis_Treatment_GMR_2025